Observational studyPediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology2026
Taste aversion and adverse events contribute equally to OIT discontinuation in children: A real-world multi-allergen analysis.
Observational study in Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Taste aversion and adverse events contribute equally to OIT discontinuation in children: A real-world multi-allergen analysis.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough oral immunotherapy (OIT) is a promising disease-modifying treatment, its real-world effectiveness is limited by the treatment burden and premature cessation. Comparative data on OIT discontinuation across allergens and non-immunological barriers remain scarce. This study investigated the rates, reasons, and timing of discontinuation in a pediatric multi-allergen cohort and identified patient phenotypes.
methodsIn this single-center observational study, pediatric patients initiating OIT between July 2022 and March 2026 were prospectively enrolled. Reasons for discontinuation were documented at cessation and supplemented by chart review. Causes were categorized as adverse events (AE) or non-AE factors (taste aversion, logistical barriers, anxiety/distress). Baseline characteristics were compared, and hierarchical clustering identified phenotypes.
resultsAmong 406 OIT courses in 307 patients, 61 (15%) were discontinued. Rates were highest for milk and lowest for cashew and sesame. AE and taste aversion were the most frequent reasons for discontinuation (41% (n = 25) and 39% (n = 24), respectively), followed by logistical barriers (11%, n = 7) and anxiety/distress (8%, n = 5). AE-related discontinuation occurred earlier in the treatment, whereas taste aversion predominated during maintenance and across ages. Patients discontinuing due to AE had higher baseline sIgE. Multi-food OIT was not associated with increased discontinuation. Exploratory cluster analysis identified three phenotypes; the high-risk cluster (high sIgE, prior severe reactions, low reactive dose) showed taste aversion as the leading cause of discontinuation.
conclusionDiscontinuation in this real-world cohort was driven equally by AE and behavioral barriers. Taste aversion emerged as a key determinant of adherence, including in younger patients. Improving OIT success requires patient-centered strategies addressing both immunological and practical barriers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.